A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at Sylmar, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Janssen Research & Development, LLC
- ID
- NCT06934226
- Phase
- Phase 3 Psoriasis Research Study
- Study Type
- Interventional
- Participants
- Expecting 675 study participants
- Last Updated